login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
KANE BIOTECH INC (KNE.CA) Stock News
Canada
-
TSX Venture Exchange
- TSX-V:KNE -
CA4838092084
-
Common Stock
0.03
CAD
0 (0%)
Last: 11/25/2025, 7:00:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
KNE.CA Latest News, Press Relases and Analysis
All
Press Releases
22 days ago - By: Kane Biotech Inc.
Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences
2 months ago - By: Kane Biotech Inc.
Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser
3 months ago - By: Kane Biotech Inc.
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
3 months ago - By: Kane Biotech Inc.
Kane Biotech Announces Second Quarter 2025 Financial Results
4 months ago - By: Kane Biotech Inc.
Kane Biotech to Present at Advanced Wound Care Summit USA
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Second Quarter 2024 Financial Results
5 months ago - By: Kane Biotech Inc.
Kane Biotech Announces Conversion of Demand Loan from Insider into an Unsecured Convertible Debenture and Annual General Meeting Voting Results
5 months ago - By: Kane Biotech Inc.
Kane Biotech Provides Further Corporate Update
6 months ago - By: Kane Biotech Inc.
Kane Biotech Announces First Quarter 2025 Financial Results
7 months ago - By: Kane Biotech Inc.
Kane Biotech Announces Closing of Private Placement Offering and Loan with Insiders of the Company
7 months ago - By: Kane Biotech Inc.
Kane Biotech Announces Fourth Quarter and Full Year 2024 Financial Results, Narrows Strategic Focus and Makes Leadership Change
8 months ago - By: Kane Biotech Inc.
Kane Biotech Announces New Agreement with Outside the Box Capital Inc.
9 months ago - By: Kane Biotech Inc.
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
9 months ago - By: Kane Biotech Inc.
Kane Biotech Announces Canadian Distribution Agreement With Best Buy Medical for revyve™ Antimicrobial Wound Gel
9 months ago - By: Kane Biotech Inc.
Kane Biotech Announces Second and Final Closing of Private Placement Offering
10 months ago - By: Kane Biotech Inc.
Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology
10 months ago - By: Kane Biotech Inc.
Kane Biotech Announces First Closing of Private Placement Offering and Extension of Private Placement Offering
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces $3,000,000 Private Placement Offering
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Third Quarter 2024 Financial Results
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
a year ago - By: Kane Biotech Inc.
Kane Biotech to Release Third Quarter 2024 Financial Results on November 28, 2024
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
a year ago - By: Kane Biotech Inc.
Kane Biotech Provides Investor Update Following FB Dermatology Acquisition Announcement
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Agreement to Acquire FB Dermatology
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Donation of revyve™ Antimicrobial Wound Gel to Ukraine
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Exclusive Distribution Agreement With XSONX
a year ago - By: Kane Biotech Inc.
Kane Biotech to Participate in a Multinational Corporate Collaboration Project
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Attendance at Upcoming Wound Care Conferences
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Exercise of Warrants
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel
a year ago - By: Kane Biotech Inc.
Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
a year ago - By: Kane Biotech Inc.
Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
a year ago - By: Kane Biotech Inc.
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
a year ago - By: Kane Biotech Inc.
Kane Biotech Announces Issuance of Restricted Share Units
a year ago - By: Kane Biotech Inc.
Kane Biotech Signs Worldwide License Agreement with Omni Bioceutical Innovations Inc.
a year ago - By: Kane Biotech Inc.
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global
a year ago - By: Kane Biotech Inc.
Kane Biotech Signs Worldwide License Agreement with Montreal-Based I-MED Pharma Inc.
2 years ago - By: Kane Biotech Inc.
Kane Biotech Announces First Quarter 2024 Financial Results
Please enable JavaScript to continue using this application.